Trial reportTheranostics2017
Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.
Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Non-small cell lung cancer and metabolism research from 2013 to 2023: a visual analysis and bibliometric study.Frontiers in oncology · 2024Pooled it
- Cross-Cancer Detectability of ctDNA Biomarkers in Asian Populations: Implications for Pan-Cancer Detection.Cancer management and research · 2026Review
- mCancer communications (London, England) · 2025Article
- Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2022Review
- Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA.Cancers · 2022Article
- Integrated analysis of necroptosis-related genes for evaluating immune infiltration and colon cancer prognosis.Frontiers in immunology · 2022Article
- Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer.Therapeutic advances in medical oncology · 2022Article
- Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma.NPJ precision oncology · 2021Article
- Tumor DNA From TumorFrontiers in oncology · 2021Article
- Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.Theranostics · 2021Article
- Article
- Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.Cancer metastasis reviews · 2020Review
- Review
- Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer.Cancer communications (London, England) · 2020Article
- Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer.Theranostics · 2020Article
- Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing.Theranostics · 2020Review
- Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.Theranostics · 2020Article
- Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.Oncology reports · 2019Article
- Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA.Acta neuropathologica · 2019Article
- OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer.Theranostics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Tao JiangDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Xuefei LiDepartment of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, P.R. China.
Jianfei WangBeijing Genecast Biotechnology Co., Beijing, P.R. China.
Chunxia SuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Wenbo HanBeijing Genecast Biotechnology Co., Beijing, P.R. China.
Chao ZhaoDepartment of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, P.R. China.
Fengying WuDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Guanghui GaoDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Wei LiDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Xiaoxia ChenDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Jiayu LiDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Fei ZhouDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Jing ZhaoDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Weijing CaiDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Henghui ZhangBeijing Genecast Biotechnology Co., Beijing, P.R. China.
Bo DuBeijing Genecast Biotechnology Co., Beijing, P.R. China.
Jun ZhangDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Shengxiang RenDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Caicun ZhouDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, P.R. China.
Hui YuDepartment of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA.
Fred R HirschDepartment of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, CO, USA.
Tongji University · CNShanghai Pulmonary Hospital · CNGenecast (China) · CNUniversity of Colorado Cancer Center · USUniversity of Iowa · US
Funding
Tissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8MNCI NIH HHS P50 CA058187
Abstract
PubMed holds no abstract for this paper.
Indexed as
Mutation AccumulationAdolescentAdultAgedAntineoplastic AgentsCarboplatinCarcinoma, Non-Small-Cell LungCell-Free Nucleic AcidsCisplatinDocetaxelFemaleHumansLung NeoplasmsMaleMiddle AgedTaxoidsAntineoplastic AgentsCarboplatinCell-Free Nucleic AcidsCisplatinDocetaxelTaxoidsTP53 protein, humanTumor Suppressor Protein p53chemotherapycirculating cell-free DNAmolecular mutational burdenNon-small-cell lung cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.